mgcd-265-analog

Description: MGCD-265 analog (Glesatinib analog) is a potent, orally bioavailable, and ATP-competitive multi-kinase inhibitor with potential antitumor activity. It inhibits c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively. MGCD265 analog has been studied in clinical trials for patients with advanced solid tumors including NSCLC, as a monotherapy and in combination with either docetaxel or erlotinib. In a phase I study, MGCD265 analog was given orally from 24 mg/m2 daily to 235 mg/m2 twice daily uninterrupted to patients with advanced solid malignancy until disease progression.

References: Bioorg Med Chem Lett. 2008 May 1; 18(9):2793-8; J Clin Oncol 28, 2010 (suppl; abstr e13595).

MGCD265-analog; Glesatinib-analog; MGCD-265-analog; MGCD 265-analog;